May 2012 | Oncology Live®

June 19, 2012

Oncology specialists who treat patients with mCRPC can look forward to choosing from an expanding array of therapeutic tools, including regimens.

June 15, 2012

An interview with David Cella, PhD, the developer of the FACIT system of questionnaires that scientifically measure the quality of life of patients being treated for cancer.

June 14, 2012

While many approaches to using immunotherapy for the treatment of prostate cancer are under study, four strategies currently in later-stage clinical development have emerged as the most promising.

June 13, 2012

The results of several long-term clinical trials published last year clarify the role of combination ADT and RT in the treatment of men with prostate cancer.

June 13, 2012

Increased understanding of the molecular mechanisms underlying the pathogenesis of hematologic cancers has led to the development of several promising new classes of targeted therapies.

June 13, 2012

JAK plays an important role in the formation and development of blood cells, and defects in the gene have been identified in myeloproliferative neoplasms.

June 11, 2012

As the cost of sequencing and analyzing genetic data continues to fall, the nation's leading cancer centers keep unveiling ambitious new clinical programs and research projects that will change the way every cancer specialist practices.

May 29, 2012

The use of PET/CT scans in the detection of early recurrence in patients with squamous cell carcinoma of the head and neck remains an open question, despite recent research suggesting beneficial results.

May 24, 2012

To learn more about how photopheresis can help patients fight the symptoms of CTCL, OncologyLive spoke with Dennis Parenti, MD, vice president of Clinical Affairs for Therakos.

May 22, 2012

Ipilimumab generates antitumor activity in some patients with advanced melanoma whose disease has metastasized to the brain without resulting in unexpected toxicities.

May 22, 2012

The demonstrated impact of imatinib mesylate on outcomes for patients with CML shifted the oncology paradigm to an intensive search for relevant molecular target.